Medical Oncology Department, Hospital General Universitario, Valencia, Spain.
Clin Transl Oncol. 2013 Dec;15(12):977-84. doi: 10.1007/s12094-013-1085-2. Epub 2013 Aug 6.
Lung cancer remains the most commonly diagnosed cancer worldwide and the leading cause of cancer-related mortality. More than 80 % of all newly diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). Despite recent advances, 40 % of patients still have advanced disease at the moment of diagnosis. Clinical information, pathological diagnosis and molecular assessment are needed to guide the systemic therapy, whereas discussion within an experienced team is key to adequately select the most appropriate multidisciplinary strategies. The purpose of this article is to provide updated recommendations for the management of these patients.
肺癌仍然是全球最常见的癌症，也是癌症相关死亡的主要原因。所有新诊断的肺癌病例中，超过 80%是非小细胞肺癌（NSCLC）。尽管最近取得了一些进展，但仍有 40%的患者在诊断时已处于晚期疾病状态。临床信息、病理诊断和分子评估是指导系统治疗的必要条件，而在经验丰富的团队中进行讨论是充分选择最合适的多学科策略的关键。本文旨在为这些患者的管理提供最新的建议。
